Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have had a diagnosis of plaque type psoriasis (psoriasis vulgaris);~* Have plaque-type psoriasis covering at least 10% of total body surface area~* Considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis~Exclusion Criteria:~* Non-plaque or drug induced forms of psoriasis~* Cannot discontinue current systemic and/or topical therapies for the treatment of psoriasis~* Cannot discontinue phototherapy~* Any uncontrolled significant medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CP 690,550 5 mg BID+Placebo BIW (Type: EXPERIMENTAL): None
- CP 690,550 10 mg BID+Placebo BIW (Type: EXPERIMENTAL): None
- Placebo BID+Etanercept 50 mg BIW (Type: ACTIVE_COMPARATOR): None
- Placebo BID+Placebo BIW (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).